FDA split over whether to approve oral type 1 diabetes drug
The US Food and Drug Administration (FDA) is split over whether the oral diabetes drug Zynquista (sotagliflozin) ought to be accredited. The US regulators have forged concern over the elevated danger of diabetic ketoacidosis (DKA) related to the drug, an oral...
